HUTCHMED Shares Are Trading Higher After the Company Announced It Completed Enrollment of the Registration Phase of Its Phase II Trial of Savolitinib in Gastric Cancer Patients With MET Amplification.
HUTCHMED Shares Are Trading Higher After the Company Announced It Completed Enrollment of the Registration Phase of Its Phase II Trial of Savolitinib in Gastric Cancer Patients With MET Amplification.
HUTCHMED的股票在公司宣佈已完成對MET擴增的胃癌患者進行Savolitinib二期試驗的註冊階段的招募後上漲。
HUTCHMED Shares Are Trading Higher After the Company Announced It Completed Enrollment of the Registration Phase of Its Phase II Trial of Savolitinib in Gastric Cancer Patients With MET Amplification.
HUTCHMED的股票在公司宣佈已完成對MET擴增的胃癌患者進行Savolitinib二期試驗的註冊階段的招募後上漲。